ReviewJournal of the American Chemical Society2017
Molecular Basis of Gut Microbiome-Associated Colorectal Cancer: A Synthetic Perspective.
Review in Journal of the American Chemical Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Total Synthesis and Structural Revision of Rhabdobranin Reveals a Cryptic Gram-Negative Antibiotic.Journal of the American Chemical Society · 2026Article
- Cellular effects of outer membrane vesicles isolated from pks-positive strains of bacteria.Research square · 2026Article
- The gut microbiome in colorectal cancer: mechanisms of carcinogenesis and emerging microbiota-targeted therapies.Discover oncology · 2026Review
- Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome.Journal of clinical medicine · 2025Review
- Structure Elucidation of Secondary Metabolites: Current Frontiers and Lingering Pitfalls.Accounts of chemical research · 2023Article
- Genotoxins: The Mechanistic Links betweenCancers · 2023Review
- Gut Microbiome in Inflammatory Bowel Disease: Role in Pathogenesis, Dietary Modulation, and Colitis-Associated Colon Cancer.Microorganisms · 2022Review
- Chemoselective and Highly Sensitive Quantification of Gut Microbiome and Human Metabolites.Angewandte Chemie (International ed. in English) · 2021Article
- Review
- Employing chemical synthesis to study the structure and function of colibactin, a "dark matter" metabolite.Natural product reports · 2020Review
- Gut Microbiota and Colon Cancer: A Role for Bacterial Protein Toxins?International journal of molecular sciences · 2020Review
- Structure and bioactivity of colibactin.Bioorganic & medicinal chemistry letters · 2020Review
- Microbiota and colorectal cancer: colibactin makes its mark.Nature reviews. Gastroenterology & hepatology · 2020Article
- Depurination of Colibactin-Derived Interstrand Cross-Links.Biochemistry · 2020Article
- Synthesis and reactivity of precolibactin 886.Nature chemistry · 2019Article
- The mysteries of macrocyclic colibactins.Nature chemistry · 2019Article
- Structure elucidation of colibactin and its DNA cross-links.Science (New York, N.Y.) · 2019Article
- Article
- Model Colibactins Exhibit Human Cell Genotoxicity in the Absence of Host Bacteria.ACS chemical biology · 2018Article
- Characterization of Natural Colibactin-Nucleobase Adducts by Tandem Mass Spectrometry and Isotopic Labeling. Support for DNA Alkylation by Cyclopropane Ring Opening.Biochemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A significant challenge toward studies of the human microbiota involves establishing causal links between bacterial metabolites and human health and disease states. Certain strains of commensal Escherichia coli harbor the 54-kb clb gene cluster which codes for small molecules named precolibactins and colibactins. Several studies suggest colibactins are genotoxins and support a role for clb metabolites in colorectal cancer formation. Significant advances toward elucidating the structures and biosynthesis of the precolibactins and colibactins have been made using genetic approaches, but their full structures remain unknown. In this Perspective we describe recent synthetic efforts that have leveraged biosynthetic advances and shed light on the mechanism of action of clb metabolites. These studies indicate that deletion of the colibactin peptidase ClbP, a modification introduced to promote accumulation of precolibactins, leads to the production of non-genotoxic pyridone-based isolates derived from the diversion of linear biosynthetic intermediates toward alternative cyclization pathways. Furthermore, these studies suggest the active genotoxins (colibactins) are unsaturated imines that are potent DNA damaging agents, thereby confirming an earlier mechanism of action hypothesis. Although these imines have very recently been detected in bacterial extracts, they have to date confounded isolation. As the power of "meta-omics" approaches to natural products discovery further advance, we anticipate that chemical synthetic and biosynthetic studies will become increasingly interdependent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.